NCT05091333View on ClinicalTrials.gov

FASENRA Regulatory Postmarketing Surveillance in Korea

CompletedOBSERVATIONAL

Enrollment

51

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions

Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)

Trial Locations (5)

Unknown

Research Site, Busan

Research Site, Gangneung-si

Research Site, Seoul

Research Site, Suwon

Research Site, Ulsan

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY